Materials and methods for making improved liposome compositions

Details Materials and methods for making improved liposome compositions Materials and methods for making improved liposome compositions

1998-12-18

2001-03-06

Kishore, Gollamudi S. (Department: 1615)

Drug, bio-affecting and body treating compositions

Preparations characterized by special physical form

Liposomes

C424S401000

Reexamination Certificate

active

06197333

ABSTRACT:

BACKGROUND OF THE INVENTION
The present invention relates generally to biologically active compounds and more specifically to compounds and peptides which are amphipathic, i.e., have both hydrophilic and hydrophobic portions. Specifically, the invention relates to improved methods for the delivery and presentation of amphipathic peptides in association with liposomes for both diagnostic and therapeutic uses.
Of particular interest to the present invention are the biologically active amphipathic peptides which are members of the family of peptide compounds including vasoactive intestinal peptide (VIP) and growth hormone releasing factor (GRF). More specifically, the invention relates to improved therapeutic methods for delivering peptides in the VIP/GRF family of peptides to targeted tissues through use of improved liposome compositions comprising a member of the VIP/GRF family of peptides and biologically active analogues thereof.
VIP is a 28-amino acid neuropeptide which is known to display a broad profile of biological actions and to activate multiple signal transducing pathways. See, Said,
Peptides
5 (Suppl. 1): 149-150 (1984) and Paul and Ebadi,
Neurochem. Int.
23:197-214 (1993). A Schiff-Edmundson projection of VIP as a &pgr;-helix reveals segregation of apolar and polar residues onto the opposite faces of the helix and that this amphipathic character is also evident when VIP is modeled as a distorted &agr;-helix, which is reported in Musso, et al.,
Biochemistiy
27:8147-8181 (1988). A correlation between the helix-forming tendency of VIP analogues and their biological activity is described in Bodan et al.,
Bioorgan. Chem.
3:133-140 (1974). In pure water, the spectral characteristics of VIP are consistent with those of a random coil. However, organic solvents and anionic lipids induce helical-information in the molecule. See, Robinson et al.,
Biopolymers
21:1217-1228 (1983); Hamed, et al.,
Biopolymers
22 :1003-1021 (1983); and Bodanszky, et al.,
Bioorganic Chem.
3:133-140 (1974).
Short peptides capable of forming amphipathic helices are known to bind and penetrate lipid bilayers. See, Kaiser and Kezdy,
Ann. Rev. Biophys. Biophysical Chem.
15:561-581 (1987) and Sansom,
Prog. Biophys. Molec. Biol.
55:139-235 (1991). Examples include model peptides like (LKKLLKL-), which are disclosed in DeGrado and Lear,
J. Am. Chem. Soc.
107:7684-7689 (1985), and the
26
-residue bee venom peptide, melittin, disclosed in Watata and Gwozdzinski,
Chem-Biol
. Interactions 82:135-149(1992). Possible mechanisms for the binding include alignment of peptide monomers parallel to the surface of the bilayer mediated by electrostatic interactions between polar amino acids and phospholipid head groups, and insertion of peptide aggregates into the apolar bilayer core, stabilized in part, by the hydrophobic effect. See,
Sansom, Prog. Biophys. Molec. Biol.
55:139235(1991).
VIP belongs to a family of homologous peptides, other members of which include peptide histidine isoleucine (PHI), peptide histidine methionine (PM), growth hormone releasing factor (GRF), pituitary adenylate cyclase activating peptide (PACAP), secretin and glucagon. Like VIP, the other members of the VIP/GRP family of peptides, and biologically active analogues thereof, can form amphipathic helices capable of binding lipid bilayers. The biological action of members of the VIP/GRF family of peptides are believed to be mediated by protein receptors expressed on the cell surface and intracellular receptors and it has recently been demonstrated that calmodulin is likely to be the intracellular receptor for VIP [Stallwood, et al.,
J. Bio. Chem.
267:19617-19621 (1992); and Stallwood, et al., FASEB J. 7:1054 (1993)].
A major factor limiting in vivo administration of VIP has been its reduced bioavailability at target tissues mostly because of proteolytic degradation, hydrolysis, and/or a multiplicity of conformations adopted by the peptide. It has been speculated that intracellular delivery of VIP alone and/or VIP-calmodulin mixtures could bypass the requirement for cell-surface binding of the peptide and thus enhance the biological actions of the peptide. Provision of the peptides expressed in and on liposomes would possibly permit intracellular delivery, since lipid bilayers of liposomes are known to fuse with the plasma membrane of cells and deliver entrapped contents into the intracellular compartment.
Characterization of the structure and properties of liposomes led to many proposed uses for the vesicle as vehicles to effect targeted drug delivery, most of which failed to materialize for any of a number of various reasons. Most prominently, the therapeutic parenteral use of conventional liposomes was found to be limited because of rapid uptake into the reticuloendothelial system by mononuclear phagocytic cells [Gregoriadias and Ryman,
Eur. J. Biochem.
27:485-491 (1972);
Beaumier
, and Hwang,
Biochem. Biophys. Acta
731:23-30 (1983)]. Uptake by this particular cell type is advantageous under the limited conditions wherein the targeted cell or tissue itself is part of the reticuloendothelial system, but uptake by phagocytic cells generally leads to degradation of compounds to be delivered, thereby posing a serious drawback to delivering a compound to other cell or tissue types.
In attempts to overcome problems inherent to liposome drug delivery, research turned to several approaches including identification of compounds which would be released back into the blood following liposome uptake by the reticuloendothelial system, alternatives to intravenous liposome administration, and use of various compounds, for example, cholesterol, to increase liposome stability in the bloodstream [Kirby, et al ,
Biochem. J.
186:591-598 (1980); Hwang, in
Liposomes from biophysics to therapeutics
, Ostro (ed.) Marcel Decker: New York (1987) pp. 109-156; Beaumier, et al.,
Res. Comm. Chem. PathoL Pharmacol.
39:227-232 (1983)]. Still other investigations examined various lipid compositions to form the liposome bilayer which more closely mimic the naturally occurring bilayer of red blood cell. Such efforts led to increased liposome half-life in circulation [Allen and Chonn,
FEBS Lett.
223:42-46 (1987); Gabizon and Papahadjopoulos,
Proc. Natl. Acad. Sci
. (USA) 85:6949-6953 (1988)].
PCT Publication WO 95/27496 and Gao, et al.,
Life Science
54:247-252 (1994) describe the use of liposomes for delivery of VIP in comparison to its delivery in aqueous solution. Encapsulation of VIP in liposomes was found to protect the peptide from proteolytic degradation and to significantly enhance the ability of VIP and to effect a decrease in mean arterial pressure in comparison to VIP in aqueous solution in hypertensive hamsters. Liposome-associated VIP was found to significantly decrease mean arterial blood pressure for a period of approximately 12 minutes, with lowest blood pressure observed almost 5 minutes after initial administration. The publication also demonstrated binding of VIP in aqueous solution to liposomes and penetration of the peptide into the liposome bilayer. It was speculated that binding of VIP to liposomes might prevent loss of peptide activity either by partitioning of the peptide into the liposome membrane, stabilizing the peptide against proteolysis, or restricting the peptide in a biologically active conformation. Whatever the reason, encapsulation of VIP in liposomes enhanced in vivo biological activity of the peptide by both prolonging the effect and increasing the magnitude of the effect in lowering blood pressure of hypertensive hamsters. Nevertheless, there remains a desire in the art to provide further improvements in the therapeutic and diagnostic delivery of biologically active peptides such as VIP.
Of interest to the present invention is the observation of increased half-life of circulating protein through conjugation of the protein to a water soluble polymer [Nucci, et al.,
Adv. Drug Del. Rev.
6:133-151(1991); Woodle, et al.,
Proc. Intern. Symp. Control. Rel. Bio

Affiliated with

Also associated with

Rating

Materials and methods for making improved liposome compositions does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Materials and methods for making improved liposome compositions, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Materials and methods for making improved liposome compositions will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2502246